Caroline Litchfield
Director of Finance/CFO bei IMMUNE DESIGN CORP
Vermögen: 7 Mio $ am 31.03.2024
Profil
Frau Caroline A. Litchfield ist Chief Financial Officer & Director bei Immune Design Corp. und Chief Financial Officer & Executive Vice President bei Merck & Co., Inc. Sie ist Mitglied des Board of Directors bei Immune Design Corp. Frau Litchfield war zuvor als Finanzdirektorin bei Merck Sharp & Dohme Ltd. beschäftigt. Sie erwarb ihren Bachelor-Abschluss an der Universität von Leicester.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MERCK & CO., INC.
0,00% | 14.02.2024 | 50 908 ( 0,00% ) | 7 Mio $ | 31.03.2024 |
Aktive Positionen von Caroline Litchfield
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMUNE DESIGN CORP | Director of Finance/CFO | - |
| MERCK & CO., INC. | Director of Finance/CFO | 01.04.2021 |
Ehemalige bekannte Positionen von Caroline Litchfield
| Unternehmen | Position | Ende |
|---|---|---|
| ORGANON & CO. | Director/Board Member | 31.05.2021 |
| FULFORD (INDIA) LIMITED | Director/Board Member | 30.01.2014 |
Organon Pharma (UK) Ltd.
 Organon Pharma (UK) Ltd. Pharmaceuticals: MajorHealth Technology Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom. | Director of Finance/CFO | 23.06.2009 |
Ausbildung von Caroline Litchfield
| University of Leicester | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ORGANON & CO. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Fulford (India) Ltd.
 Fulford (India) Ltd. Pharmaceuticals: MajorHealth Technology Fulford (India) Ltd. engages in the wholesale of pharmaceutical and medical goods. Its products include speciality health care and fertility, oncology, quadriderm, elocon, elosalic, dipsalic, and emolene. The company was founded on March 2, 1948 and is headquartered in Mumbai, India. | Health Technology |
Organon Pharma (UK) Ltd.
Organon Pharma (UK) Ltd. Pharmaceuticals: MajorHealth Technology Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom. | Health Technology |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
